



EOS imaging secures a Standby Equity Facility

Paris, 16 June 2014 : EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, eligible for PEA-PME equity savings plans, announced today that it has entered into a Standby Equity Facility (PACEO®) with Société Générale as authorized by the Shareholders' Meeting of June 13, 2013.

Under the terms of the agreement Société Générale has committed to purchase newly created shares at any time during the 36-month commitment period, within the global limit of 1,800,000 shares, being 9.8% of the 18,377,878 shares currently outstanding.

Should the entire standby equity facility be drawn down and resulting in the issuance of 1,800,000 new shares, a shareholder who currently owns 1% of the company's share capital would experience a reduction of his / her ownership to 0.91%¹.

For each tranche, the price to be paid equals the volume weighted average share price of the three trading days preceding the effective date of purchase with a discount capped at 5% dependent on the size of the drawdown. This discount allows Société Générale, who is not positioned as a long term shareholder in the Company, to purchase the shares independently of market volatility, and in compliance with the article 212-5, 1° du Règlement général de l'Autorité des marchés financiers.

"The implementation of this standby Equity Facility is as *flexible and guaranteed solution for our future development*" said Marie Meynadier, CEO of EOS imaging.

EOS imaging has no minimum drawdown obligation, and will use the facility at its sole discretion if market conditions are favorable and in the best interests of both the Company and its shareholders.

About EOS imaging

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of over 90 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employs 101 people including an R&D team of 38 engineers. The Group is based in Paris and has four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

For further information, please visit: www.eos-imaging.com.

¹ Based on 18,377,878 shares representing EOS imaging share capital



EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1st half of 2014, on July 22, 2014 (after market).



Contacts:

Anne Renevot
CFO
Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.
Investor relations & Strategic communications
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

NewCap. Media
Press Relations – A.F Loyer
Tel.: +33 (0)1 44 71 00 12
afloyer@newcap.fr

Société Générale
Frédéric Sutterlin
frederic.sutterlin@sgcib.com
Tel.: +33 (0)1 42 13 59 14

EOS imaging will participate to the French Life Sciences Days

« FRENCH LIFE SCIENCES DAYS »
25 & 26 juin 2014

